Fundies.
English

Segment disclosures

Company overview

COVETRUS, INC.

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

67 dimension combinations 547 retained observations 19 reported periods

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Material Reconciling Items · Asia Pacificand Emerging Markets

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:MaterialReconcilingItemsMember;us-gaap:StatementBusinessSegmentsAxis=cvet:AsiaPacificandEmergingMarketsMember
PeriodValueUnitFiledEvidence
2021-07-01 – 2021-09-300 USD20211104Open filing evidence
2021-01-01 – 2021-09-300 USD20211104Open filing evidence
2020-01-01 – 2020-12-310 USD20210301Open filing evidence
2020-07-01 – 2020-09-300 USD20211104Open filing evidence
2020-01-01 – 2020-09-300 USD20211104Open filing evidence
2020-01-01 – 2020-03-310 USD20200514Open filing evidence
2018-12-30 – 2019-12-310 USD20210301Open filing evidence
2018-12-30 – 2019-03-310 USD20200514Open filing evidence
2017-12-31 – 2018-12-290 USD20210301Open filing evidence
2017-01-01 – 2017-12-300 USD20200303Open filing evidence

Material Reconciling Items · Europe Segment

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:MaterialReconcilingItemsMember;us-gaap:StatementBusinessSegmentsAxis=cvet:EuropeSegmentMember
PeriodValueUnitFiledEvidence
2021-07-01 – 2021-09-30-4000000 USD20211104Open filing evidence
2021-01-01 – 2021-09-30-14000000 USD20211104Open filing evidence
2021-01-01 – 2021-03-31-6000000 USD20210506Open filing evidence
2020-07-01 – 2020-09-30-3000000 USD20211104Open filing evidence
2020-01-01 – 2020-09-30-9000000 USD20211104Open filing evidence
2020-01-01 – 2020-03-31-4000000 USD20210506Open filing evidence
2018-12-30 – 2019-12-31-14000000 USD20200303Open filing evidence
2018-12-30 – 2019-03-31-3000000 USD20200514Open filing evidence
2017-12-31 – 2018-12-29-10000000 USD20200303Open filing evidence
2017-01-01 – 2017-12-303000000 USD20200303Open filing evidence

Material Reconciling Items · North America Segment

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:MaterialReconcilingItemsMember;us-gaap:StatementBusinessSegmentsAxis=cvet:NorthAmericaSegmentMember
PeriodValueUnitFiledEvidence
2021-01-01 – 2021-12-31-93000000 USD20220228Open filing evidence
2021-01-01 – 2021-03-31-22000000 USD20210506Open filing evidence
2020-01-01 – 2020-12-31-76000000 USD20220228Open filing evidence
2020-01-01 – 2020-03-31-16000000 USD20210506Open filing evidence
2018-12-30 – 2019-12-31-33000000 USD20220228Open filing evidence
2018-12-30 – 2019-03-31-1000000 USD20200514Open filing evidence
2017-12-31 – 2018-12-29-2000000 USD20200303Open filing evidence
2017-01-01 – 2017-12-30-2000000 USD20200303Open filing evidence

Operating Segments · Prescription Management · Asia Pacificand Emerging Markets

Consolidation Items · Product Or Service · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cvet:PrescriptionManagementMember;us-gaap:StatementBusinessSegmentsAxis=cvet:AsiaPacificandEmergingMarketsMember
PeriodValueUnitFiledEvidence
2022-04-01 – 2022-06-300 USD20220804Open filing evidence
2022-01-01 – 2022-06-300 USD20220804Open filing evidence
2021-04-01 – 2021-06-300 USD20220804Open filing evidence
2021-01-01 – 2021-06-300 USD20220804Open filing evidence
2020-01-01 – 2020-03-310 USD20200514Open filing evidence
2018-12-30 – 2019-12-310 USD20200303Open filing evidence
2018-12-30 – 2019-03-310 USD20200514Open filing evidence
2017-12-31 – 2018-12-290 USD20200303Open filing evidence
2017-01-01 – 2017-12-300 USD20200303Open filing evidence

Operating Segments · Prescription Management · Europe Segment

Consolidation Items · Product Or Service · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cvet:PrescriptionManagementMember;us-gaap:StatementBusinessSegmentsAxis=cvet:EuropeSegmentMember
PeriodValueUnitFiledEvidence
2022-04-01 – 2022-06-300 USD20220804Open filing evidence
2022-01-01 – 2022-06-300 USD20220804Open filing evidence
2021-04-01 – 2021-06-300 USD20220804Open filing evidence
2021-01-01 – 2021-06-300 USD20220804Open filing evidence
2021-01-01 – 2021-03-310 USD20210506Open filing evidence
2020-01-01 – 2020-03-310 USD20210506Open filing evidence
2018-12-30 – 2019-12-310 USD20200303Open filing evidence
2018-12-30 – 2019-03-310 USD20200514Open filing evidence
2017-12-31 – 2018-12-290 USD20200303Open filing evidence
2017-01-01 – 2017-12-300 USD20200303Open filing evidence

Operating Segments · Prescription Management · North America Segment

Consolidation Items · Product Or Service · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cvet:PrescriptionManagementMember;us-gaap:StatementBusinessSegmentsAxis=cvet:NorthAmericaSegmentMember
PeriodValueUnitFiledEvidence
2021-01-01 – 2021-03-31112000000 USD20210506Open filing evidence
2020-01-01 – 2020-03-3184000000 USD20210506Open filing evidence
2018-12-30 – 2019-12-31246000000 USD20200303Open filing evidence
2018-12-30 – 2019-03-3134000000 USD20200514Open filing evidence
2017-12-31 – 2018-12-290 USD20200303Open filing evidence
2017-01-01 – 2017-12-300 USD20200303Open filing evidence

Operating Segments · Software Solutions · Asia Pacificand Emerging Markets

Consolidation Items · Product Or Service · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cvet:SoftwareSolutionsMember;us-gaap:StatementBusinessSegmentsAxis=cvet:AsiaPacificandEmergingMarketsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-312000000 USD20200514Open filing evidence
2018-12-30 – 2019-12-317000000 USD20200303Open filing evidence
2018-12-30 – 2019-03-312000000 USD20200514Open filing evidence
2017-12-31 – 2018-12-297000000 USD20200303Open filing evidence
2017-01-01 – 2017-12-307000000 USD20200303Open filing evidence

Operating Segments · Software Solutions · Europe Segment

Consolidation Items · Product Or Service · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cvet:SoftwareSolutionsMember;us-gaap:StatementBusinessSegmentsAxis=cvet:EuropeSegmentMember
PeriodValueUnitFiledEvidence
2021-01-01 – 2021-03-313000000 USD20210506Open filing evidence
2020-04-01 – 2020-06-302000000 USD20200811Open filing evidence
2020-01-01 – 2020-06-304000000 USD20200811Open filing evidence
2020-01-01 – 2020-03-312000000 USD20210506Open filing evidence
2018-12-30 – 2019-12-3110000000 USD20200303Open filing evidence
2019-04-01 – 2019-06-303000000 USD20200811Open filing evidence
2018-12-30 – 2019-06-305000000 USD20200811Open filing evidence
2018-12-30 – 2019-03-312000000 USD20200514Open filing evidence
2017-12-31 – 2018-12-2911000000 USD20200303Open filing evidence
2017-01-01 – 2017-12-3011000000 USD20200303Open filing evidence

Operating Segments · Software Solutions · North America Segment

Consolidation Items · Product Or Service · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cvet:SoftwareSolutionsMember;us-gaap:StatementBusinessSegmentsAxis=cvet:NorthAmericaSegmentMember
PeriodValueUnitFiledEvidence
2021-01-01 – 2021-03-3120000000 USD20210506Open filing evidence
2020-01-01 – 2020-03-3120000000 USD20210506Open filing evidence
2018-12-30 – 2019-12-3182000000 USD20200303Open filing evidence
2018-12-30 – 2019-03-3122000000 USD20200514Open filing evidence
2017-12-31 – 2018-12-2983000000 USD20200303Open filing evidence
2017-01-01 – 2017-12-3083000000 USD20200303Open filing evidence

Operating Segments · Supply Chain · Asia Pacificand Emerging Markets

Consolidation Items · Product Or Service · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cvet:SupplyChainMember;us-gaap:StatementBusinessSegmentsAxis=cvet:AsiaPacificandEmergingMarketsMember
PeriodValueUnitFiledEvidence
2021-01-01 – 2021-03-31109000000 USD20210506Open filing evidence
2020-01-01 – 2020-03-3193000000 USD20210506Open filing evidence
2018-12-30 – 2019-12-31361000000 USD20200303Open filing evidence
2018-12-30 – 2019-03-3184000000 USD20200514Open filing evidence
2017-12-31 – 2018-12-29380000000 USD20200303Open filing evidence
2017-01-01 – 2017-12-30342000000 USD20200303Open filing evidence

Operating Segments · Supply Chain · Europe Segment

Consolidation Items · Product Or Service · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cvet:SupplyChainMember;us-gaap:StatementBusinessSegmentsAxis=cvet:EuropeSegmentMember
PeriodValueUnitFiledEvidence
2021-01-01 – 2021-03-31364000000 USD20210506Open filing evidence
2020-01-01 – 2020-03-31424000000 USD20210506Open filing evidence
2018-12-30 – 2019-12-311513000000 USD20200303Open filing evidence
2018-12-30 – 2019-03-31362000000 USD20200514Open filing evidence
2017-12-31 – 2018-12-291462000000 USD20200303Open filing evidence
2017-01-01 – 2017-12-301359000000 USD20200303Open filing evidence

Operating Segments · Supply Chain · North America Segment

Consolidation Items · Product Or Service · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cvet:SupplyChainMember;us-gaap:StatementBusinessSegmentsAxis=cvet:NorthAmericaSegmentMember
PeriodValueUnitFiledEvidence
2021-01-01 – 2021-03-31525000000 USD20210506Open filing evidence
2020-01-01 – 2020-03-31462000000 USD20210506Open filing evidence
2018-12-30 – 2019-12-311816000000 USD20200303Open filing evidence
2018-12-30 – 2019-03-31442000000 USD20200514Open filing evidence
2017-12-31 – 2018-12-291858000000 USD20200303Open filing evidence
2017-01-01 – 2017-12-301795000000 USD20200303Open filing evidence

Operating Segments · APA Cand Emerging Markets

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cvet:APACandEmergingMarketsMember
PeriodValueUnitFiledEvidence
2019-07-01 – 2019-09-3094000000 USD20191112Open filing evidence
2018-12-30 – 2019-09-30270000000 USD20191112Open filing evidence
2019-04-01 – 2019-06-3090000000 USD20190813Open filing evidence
2018-12-30 – 2019-06-30176000000 USD20190813Open filing evidence
2018-12-30 – 2019-03-3186000000 USD20190607Open filing evidence
2018-07-01 – 2018-09-3095000000 USD20191112Open filing evidence
2017-12-31 – 2018-09-30291000000 USD20191112Open filing evidence
2018-04-01 – 2018-06-3098000000 USD20190813Open filing evidence
2017-12-31 – 2018-06-30196000000 USD20190813Open filing evidence
2017-12-31 – 2018-03-3198000000 USD20190607Open filing evidence

Operating Segments · Asia Pacificand Emerging Markets

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cvet:AsiaPacificandEmergingMarketsMember
PeriodValueUnitFiledEvidence
2022-04-01 – 2022-06-30109000000 USD20220804Open filing evidence
2022-01-01 – 2022-06-30221000000 USD20220804Open filing evidence
2021-07-01 – 2021-09-30116000000 USD20211104Open filing evidence
2021-01-01 – 2021-09-30342000000 USD20211104Open filing evidence
2021-04-01 – 2021-06-30114000000 USD20220804Open filing evidence
2021-01-01 – 2021-06-30226000000 USD20220804Open filing evidence
2021-01-01 – 2021-03-31112000000 USD20210506Open filing evidence
2020-07-01 – 2020-09-30108000000 USD20211104Open filing evidence
2020-01-01 – 2020-09-30288000000 USD20211104Open filing evidence
2020-04-01 – 2020-06-3085000000 USD20200811Open filing evidence
2020-01-01 – 2020-06-30180000000 USD20200811Open filing evidence
2020-01-01 – 2020-03-3195000000 USD20210506Open filing evidence
2018-12-30 – 2019-12-31368000000 USD20200303Open filing evidence
2019-04-01 – 2019-06-3090000000 USD20200811Open filing evidence
2018-12-30 – 2019-06-30176000000 USD20200811Open filing evidence
2018-12-30 – 2019-03-3186000000 USD20200514Open filing evidence
2017-12-31 – 2018-12-29387000000 USD20200303Open filing evidence
2017-01-01 – 2017-12-30349000000 USD20200303Open filing evidence

Operating Segments · Asia Pacificand Emerging Markets · Prescription Management

Consolidation Items · Statement Business Segments · Product Or Service

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cvet:AsiaPacificandEmergingMarketsMember;srt:ProductOrServiceAxis=cvet:PrescriptionManagementMember
PeriodValueUnitFiledEvidence
2021-01-01 – 2021-03-310 USD20210506Open filing evidence
2020-04-01 – 2020-06-300 USD20200811Open filing evidence
2020-01-01 – 2020-06-300 USD20200811Open filing evidence
2020-01-01 – 2020-03-310 USD20210506Open filing evidence
2019-04-01 – 2019-06-300 USD20200811Open filing evidence
2018-12-30 – 2019-06-300 USD20200811Open filing evidence

Operating Segments · Asia Pacificand Emerging Markets · Software Solutions

Consolidation Items · Statement Business Segments · Product Or Service

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cvet:AsiaPacificandEmergingMarketsMember;srt:ProductOrServiceAxis=cvet:SoftwareSolutionsMember
PeriodValueUnitFiledEvidence
2021-01-01 – 2021-03-313000000 USD20210506Open filing evidence
2020-04-01 – 2020-06-302000000 USD20200811Open filing evidence
2020-01-01 – 2020-06-304000000 USD20200811Open filing evidence
2020-01-01 – 2020-03-312000000 USD20210506Open filing evidence
2019-04-01 – 2019-06-302000000 USD20200811Open filing evidence
2018-12-30 – 2019-06-304000000 USD20200811Open filing evidence

Operating Segments · Asia Pacificand Emerging Markets · Supply Chain

Consolidation Items · Statement Business Segments · Product Or Service

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cvet:AsiaPacificandEmergingMarketsMember;srt:ProductOrServiceAxis=cvet:SupplyChainMember
PeriodValueUnitFiledEvidence
2022-04-01 – 2022-06-30107000000 USD20220804Open filing evidence
2022-01-01 – 2022-06-30216000000 USD20220804Open filing evidence
2021-04-01 – 2021-06-30112000000 USD20220804Open filing evidence
2021-01-01 – 2021-06-30221000000 USD20220804Open filing evidence
2020-04-01 – 2020-06-3083000000 USD20200811Open filing evidence
2020-01-01 – 2020-06-30176000000 USD20200811Open filing evidence
2019-04-01 – 2019-06-3088000000 USD20200811Open filing evidence
2018-12-30 – 2019-06-30172000000 USD20200811Open filing evidence

Operating Segments · Europe Segment

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cvet:EuropeSegmentMember
PeriodValueUnitFiledEvidence
2022-04-01 – 2022-06-30327000000 USD20220804Open filing evidence
2022-01-01 – 2022-06-30671000000 USD20220804Open filing evidence
2021-04-01 – 2021-06-30366000000 USD20220804Open filing evidence
2021-01-01 – 2021-06-30727000000 USD20220804Open filing evidence
2021-01-01 – 2021-03-31361000000 USD20210506Open filing evidence
2020-07-01 – 2020-09-30403000000 USD20201110Open filing evidence
2020-01-01 – 2020-09-301166000000 USD20201110Open filing evidence
2020-04-01 – 2020-06-30342000000 USD20210805Open filing evidence
2020-01-01 – 2020-06-30764000000 USD20210805Open filing evidence
2020-01-01 – 2020-03-31422000000 USD20210506Open filing evidence
2018-12-30 – 2019-12-311509000000 USD20200303Open filing evidence
2019-07-01 – 2019-09-30384000000 USD20201110Open filing evidence
2018-12-30 – 2019-09-301114000000 USD20201110Open filing evidence
2019-04-01 – 2019-06-30370000000 USD20200811Open filing evidence
2018-12-30 – 2019-06-30731000000 USD20200811Open filing evidence
2018-12-30 – 2019-03-31361000000 USD20200514Open filing evidence
2017-12-31 – 2018-12-291463000000 USD20200303Open filing evidence
2017-01-01 – 2017-12-301373000000 USD20200303Open filing evidence

Operating Segments · Europe Segment · Prescription Management

Consolidation Items · Statement Business Segments · Product Or Service

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cvet:EuropeSegmentMember;srt:ProductOrServiceAxis=cvet:PrescriptionManagementMember
PeriodValueUnitFiledEvidence
2021-04-01 – 2021-06-300 USD20210805Open filing evidence
2021-01-01 – 2021-06-300 USD20210805Open filing evidence
2020-04-01 – 2020-06-300 USD20210805Open filing evidence
2020-01-01 – 2020-06-300 USD20210805Open filing evidence
2019-04-01 – 2019-06-300 USD20200811Open filing evidence
2018-12-30 – 2019-06-300 USD20200811Open filing evidence

Operating Segments · Europe Segment · Supply Chain

Consolidation Items · Statement Business Segments · Product Or Service

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cvet:EuropeSegmentMember;srt:ProductOrServiceAxis=cvet:SupplyChainMember
PeriodValueUnitFiledEvidence
2022-04-01 – 2022-06-30323000000 USD20220804Open filing evidence
2022-01-01 – 2022-06-30660000000 USD20220804Open filing evidence
2021-04-01 – 2021-06-30360000000 RestatedUSD20220804Open filing evidence
2021-01-01 – 2021-06-30712000000 RestatedUSD20220804Open filing evidence
2020-07-01 – 2020-09-30404000000 USD20201110Open filing evidence
2020-01-01 – 2020-09-301169000000 USD20201110Open filing evidence
2020-04-01 – 2020-06-30342000000 USD20210805Open filing evidence
2020-01-01 – 2020-06-30766000000 USD20210805Open filing evidence
2019-07-01 – 2019-09-30385000000 USD20201110Open filing evidence
2018-12-30 – 2019-09-301117000000 USD20201110Open filing evidence
2019-04-01 – 2019-06-30370000000 USD20200811Open filing evidence
2018-12-30 – 2019-06-30733000000 USD20200811Open filing evidence

Operating Segments · North America Segment

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cvet:NorthAmericaSegmentMember
PeriodValueUnitFiledEvidence
2021-01-01 – 2021-03-31635000000 USD20210506Open filing evidence
2020-07-01 – 2020-09-30618000000 USD20201110Open filing evidence
2020-01-01 – 2020-09-301771000000 USD20201110Open filing evidence
2020-04-01 – 2020-06-30602000000 USD20200811Open filing evidence
2020-01-01 – 2020-06-301152000000 USD20200811Open filing evidence
2020-01-01 – 2020-03-31550000000 USD20210506Open filing evidence
2018-12-30 – 2019-12-312111000000 USD20200303Open filing evidence
2019-07-01 – 2019-09-30543000000 USD20201110Open filing evidence
2018-12-30 – 2019-09-301592000000 USD20201110Open filing evidence
2019-04-01 – 2019-06-30552000000 USD20200811Open filing evidence
2018-12-30 – 2019-06-301049000000 USD20200811Open filing evidence
2018-12-30 – 2019-03-31497000000 USD20200514Open filing evidence
2017-12-31 – 2018-12-291939000000 USD20200303Open filing evidence
2017-01-01 – 2017-12-301876000000 USD20200303Open filing evidence

Operating Segments · North America Segment · Prescription Management

Consolidation Items · Statement Business Segments · Product Or Service

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cvet:NorthAmericaSegmentMember;srt:ProductOrServiceAxis=cvet:PrescriptionManagementMember
PeriodValueUnitFiledEvidence
2020-04-01 – 2020-06-30110000000 USD20200811Open filing evidence
2020-01-01 – 2020-06-30195000000 USD20200811Open filing evidence
2019-04-01 – 2019-06-3067000000 USD20200811Open filing evidence
2018-12-30 – 2019-06-30100000000 USD20200811Open filing evidence

Operating Segments · North America Segment · Software Solutions

Consolidation Items · Statement Business Segments · Product Or Service

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cvet:NorthAmericaSegmentMember;srt:ProductOrServiceAxis=cvet:SoftwareSolutionsMember
PeriodValueUnitFiledEvidence
2020-04-01 – 2020-06-3019000000 USD20200811Open filing evidence
2020-01-01 – 2020-06-3040000000 USD20200811Open filing evidence
2019-04-01 – 2019-06-3020000000 USD20200811Open filing evidence
2018-12-30 – 2019-06-3042000000 USD20200811Open filing evidence

Operating Segments · North America Segment · Supply Chain

Consolidation Items · Statement Business Segments · Product Or Service

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cvet:NorthAmericaSegmentMember;srt:ProductOrServiceAxis=cvet:SupplyChainMember
PeriodValueUnitFiledEvidence
2020-07-01 – 2020-09-30512000000 USD20201110Open filing evidence
2020-01-01 – 2020-09-301469000000 USD20201110Open filing evidence
2020-04-01 – 2020-06-30495000000 USD20200811Open filing evidence
2020-01-01 – 2020-06-30956000000 USD20200811Open filing evidence
2019-07-01 – 2019-09-30464000000 USD20201110Open filing evidence
2018-12-30 – 2019-09-301379000000 USD20201110Open filing evidence
2019-04-01 – 2019-06-30472000000 USD20200811Open filing evidence
2018-12-30 – 2019-06-30915000000 USD20200811Open filing evidence

Operating Segments · Europe

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=srt:EuropeMember
PeriodValueUnitFiledEvidence
2019-07-01 – 2019-09-30384000000 USD20191112Open filing evidence
2018-12-30 – 2019-09-301114000000 USD20191112Open filing evidence
2019-04-01 – 2019-06-30370000000 USD20190813Open filing evidence
2018-12-30 – 2019-06-30731000000 USD20190813Open filing evidence
2018-12-30 – 2019-03-31361000000 USD20190607Open filing evidence
2018-07-01 – 2018-09-30351000000 USD20191112Open filing evidence
2017-12-31 – 2018-09-301113000000 USD20191112Open filing evidence
2018-04-01 – 2018-06-30390000000 USD20190813Open filing evidence
2017-12-31 – 2018-06-30761000000 USD20190813Open filing evidence
2017-12-31 – 2018-03-31369000000 USD20190607Open filing evidence

Operating Segments · North America

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=srt:NorthAmericaMember
PeriodValueUnitFiledEvidence
2019-07-01 – 2019-09-30543000000 USD20191112Open filing evidence
2018-12-30 – 2019-09-301592000000 USD20191112Open filing evidence
2019-04-01 – 2019-06-30552000000 USD20190813Open filing evidence
2018-12-30 – 2019-06-301049000000 USD20190813Open filing evidence
2018-12-30 – 2019-03-31497000000 USD20190607Open filing evidence
2018-07-01 – 2018-09-30479000000 USD20191112Open filing evidence
2017-12-31 – 2018-09-301479000000 USD20191112Open filing evidence
2018-04-01 – 2018-06-30520000000 USD20190813Open filing evidence
2017-12-31 – 2018-06-301001000000 USD20190813Open filing evidence
2017-12-31 – 2018-03-31480000000 USD20190607Open filing evidence

Prescription Management · Operating Segments · Asia Pacificand Emerging Markets

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=cvet:PrescriptionManagementMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cvet:AsiaPacificandEmergingMarketsMember
PeriodValueUnitFiledEvidence
2021-07-01 – 2021-09-300 USD20211104Open filing evidence
2021-01-01 – 2021-09-300 USD20211104Open filing evidence
2020-07-01 – 2020-09-300 USD20211104Open filing evidence
2020-01-01 – 2020-09-300 USD20211104Open filing evidence

Prescription Management · Operating Segments · Europe Segment

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=cvet:PrescriptionManagementMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cvet:EuropeSegmentMember
PeriodValueUnitFiledEvidence
2020-07-01 – 2020-09-300 USD20201110Open filing evidence
2020-01-01 – 2020-09-300 USD20201110Open filing evidence
2019-07-01 – 2019-09-300 USD20201110Open filing evidence
2018-12-30 – 2019-09-300 USD20201110Open filing evidence

Prescription Management · Operating Segments · North America Segment

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=cvet:PrescriptionManagementMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cvet:NorthAmericaSegmentMember
PeriodValueUnitFiledEvidence
2020-07-01 – 2020-09-30104000000 USD20201110Open filing evidence
2020-01-01 – 2020-09-30298000000 USD20201110Open filing evidence
2019-07-01 – 2019-09-3072000000 USD20201110Open filing evidence
2018-12-30 – 2019-09-30172000000 USD20201110Open filing evidence

Prescription Management · Asia Pacificand Emerging Markets · Operating Segments

Product Or Service · Statement Business Segments · Consolidation Items

Source dimensions srt:ProductOrServiceAxis=cvet:PrescriptionManagementMember;us-gaap:StatementBusinessSegmentsAxis=cvet:AsiaPacificandEmergingMarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2020-07-01 – 2020-09-300 USD20201110Open filing evidence
2020-01-01 – 2020-09-300 USD20201110Open filing evidence
2019-07-01 – 2019-09-300 USD20201110Open filing evidence
2018-12-30 – 2019-09-300 USD20201110Open filing evidence

Prescription Management · Europe Segment · Operating Segments

Product Or Service · Statement Business Segments · Consolidation Items

Source dimensions srt:ProductOrServiceAxis=cvet:PrescriptionManagementMember;us-gaap:StatementBusinessSegmentsAxis=cvet:EuropeSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2021-07-01 – 2021-09-300 USD20211104Open filing evidence
2021-01-01 – 2021-09-300 USD20211104Open filing evidence
2020-07-01 – 2020-09-300 USD20211104Open filing evidence
2020-01-01 – 2020-09-300 USD20211104Open filing evidence

Software Solutions · Operating Segments · Asia Pacificand Emerging Markets

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=cvet:SoftwareSolutionsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cvet:AsiaPacificandEmergingMarketsMember
PeriodValueUnitFiledEvidence
2022-04-01 – 2022-06-302000000 USD20220804Open filing evidence
2022-01-01 – 2022-06-305000000 USD20220804Open filing evidence
2021-07-01 – 2021-09-302000000 USD20211104Open filing evidence
2021-01-01 – 2021-09-307000000 USD20211104Open filing evidence
2021-04-01 – 2021-06-302000000 USD20220804Open filing evidence
2021-01-01 – 2021-06-305000000 USD20220804Open filing evidence
2020-07-01 – 2020-09-302000000 USD20211104Open filing evidence
2020-01-01 – 2020-09-306000000 USD20211104Open filing evidence

Software Solutions · Operating Segments · Europe Segment

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=cvet:SoftwareSolutionsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cvet:EuropeSegmentMember
PeriodValueUnitFiledEvidence
2022-04-01 – 2022-06-302000000 USD20220804Open filing evidence
2022-01-01 – 2022-06-305000000 USD20220804Open filing evidence
2021-04-01 – 2021-06-302000000 USD20220804Open filing evidence
2021-01-01 – 2021-06-305000000 USD20220804Open filing evidence
2020-07-01 – 2020-09-302000000 USD20201110Open filing evidence
2020-01-01 – 2020-09-306000000 USD20201110Open filing evidence
2020-04-01 – 2020-06-302000000 USD20210805Open filing evidence
2020-01-01 – 2020-06-304000000 USD20210805Open filing evidence
2019-07-01 – 2019-09-302000000 USD20201110Open filing evidence
2018-12-30 – 2019-09-307000000 USD20201110Open filing evidence

Software Solutions · Operating Segments · North America Segment

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=cvet:SoftwareSolutionsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cvet:NorthAmericaSegmentMember
PeriodValueUnitFiledEvidence
2020-07-01 – 2020-09-3020000000 USD20201110Open filing evidence
2020-01-01 – 2020-09-3060000000 USD20201110Open filing evidence
2019-07-01 – 2019-09-3020000000 USD20201110Open filing evidence
2018-12-30 – 2019-09-3062000000 USD20201110Open filing evidence

Software Solutions · Asia Pacificand Emerging Markets · Operating Segments

Product Or Service · Statement Business Segments · Consolidation Items

Source dimensions srt:ProductOrServiceAxis=cvet:SoftwareSolutionsMember;us-gaap:StatementBusinessSegmentsAxis=cvet:AsiaPacificandEmergingMarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2021-01-01 – 2021-12-319000000 USD20220228Open filing evidence
2020-01-01 – 2020-12-318000000 USD20220228Open filing evidence
2020-07-01 – 2020-09-302000000 USD20201110Open filing evidence
2020-01-01 – 2020-09-306000000 USD20201110Open filing evidence
2018-12-30 – 2019-12-317000000 USD20220228Open filing evidence
2019-07-01 – 2019-09-302000000 USD20201110Open filing evidence
2018-12-30 – 2019-09-306000000 USD20201110Open filing evidence
2017-12-31 – 2018-12-297000000 USD20210301Open filing evidence

Software Solutions · Europe Segment · Operating Segments

Product Or Service · Statement Business Segments · Consolidation Items

Source dimensions srt:ProductOrServiceAxis=cvet:SoftwareSolutionsMember;us-gaap:StatementBusinessSegmentsAxis=cvet:EuropeSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2021-01-01 – 2021-12-3111000000 USD20220228Open filing evidence
2021-07-01 – 2021-09-303000000 USD20211104Open filing evidence
2021-01-01 – 2021-09-308000000 USD20211104Open filing evidence
2020-01-01 – 2020-12-3110000000 USD20220228Open filing evidence
2020-07-01 – 2020-09-302000000 USD20211104Open filing evidence
2020-01-01 – 2020-09-306000000 USD20211104Open filing evidence
2018-12-30 – 2019-12-3110000000 USD20220228Open filing evidence

Software Solutions · North America Segment · Operating Segments

Product Or Service · Statement Business Segments · Consolidation Items

Source dimensions srt:ProductOrServiceAxis=cvet:SoftwareSolutionsMember;us-gaap:StatementBusinessSegmentsAxis=cvet:NorthAmericaSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2022-04-01 – 2022-06-3021000000 USD20220804Open filing evidence
2022-01-01 – 2022-06-3040000000 USD20220804Open filing evidence
2021-01-01 – 2021-12-3179000000 USD20220228Open filing evidence
2021-04-01 – 2021-06-3020000000 USD20220804Open filing evidence
2021-01-01 – 2021-06-3040000000 USD20220804Open filing evidence
2020-01-01 – 2020-12-3178000000 USD20220228Open filing evidence
2020-04-01 – 2020-06-3019000000 USD20210805Open filing evidence
2020-01-01 – 2020-06-3040000000 USD20210805Open filing evidence
2018-12-30 – 2019-12-3182000000 USD20220228Open filing evidence
2017-12-31 – 2018-12-2983000000 USD20210301Open filing evidence

Supply Chain · Operating Segments · Asia Pacificand Emerging Markets

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=cvet:SupplyChainMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cvet:AsiaPacificandEmergingMarketsMember
PeriodValueUnitFiledEvidence
2021-07-01 – 2021-09-30114000000 USD20211104Open filing evidence
2021-01-01 – 2021-09-30335000000 USD20211104Open filing evidence
2020-07-01 – 2020-09-30106000000 USD20211104Open filing evidence
2020-01-01 – 2020-09-30282000000 USD20211104Open filing evidence

Supply Chain · Asia Pacificand Emerging Markets · Operating Segments

Product Or Service · Statement Business Segments · Consolidation Items

Source dimensions srt:ProductOrServiceAxis=cvet:SupplyChainMember;us-gaap:StatementBusinessSegmentsAxis=cvet:AsiaPacificandEmergingMarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2021-01-01 – 2021-12-31452000000 USD20220228Open filing evidence
2020-01-01 – 2020-12-31394000000 USD20220228Open filing evidence
2018-12-30 – 2019-12-31361000000 USD20220228Open filing evidence
2017-12-31 – 2018-12-29380000000 USD20210301Open filing evidence

Supply Chain · Europe Segment · Operating Segments

Product Or Service · Statement Business Segments · Consolidation Items

Source dimensions srt:ProductOrServiceAxis=cvet:SupplyChainMember;us-gaap:StatementBusinessSegmentsAxis=cvet:EuropeSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2021-01-01 – 2021-12-311419000000 USD20220228Open filing evidence
2021-07-01 – 2021-09-30354000000 USD20211104Open filing evidence
2021-01-01 – 2021-09-301086000000 USD20211104Open filing evidence
2020-01-01 – 2020-12-311574000000 USD20220228Open filing evidence
2020-07-01 – 2020-09-30404000000 USD20211104Open filing evidence
2020-01-01 – 2020-09-301169000000 USD20211104Open filing evidence
2018-12-30 – 2019-12-311513000000 USD20220228Open filing evidence

Supply Chain · North America Segment · Operating Segments

Product Or Service · Statement Business Segments · Consolidation Items

Source dimensions srt:ProductOrServiceAxis=cvet:SupplyChainMember;us-gaap:StatementBusinessSegmentsAxis=cvet:NorthAmericaSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2021-01-01 – 2021-12-312230000000 USD20220228Open filing evidence
2020-01-01 – 2020-12-311969000000 USD20220228Open filing evidence
2018-12-30 – 2019-12-311816000000 USD20220228Open filing evidence
2017-12-31 – 2018-12-291858000000 USD20210301Open filing evidence

Asia Pacificand Emerging Markets

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cvet:AsiaPacificandEmergingMarketsMember
PeriodValueUnitFiledEvidence
2022-04-01 – 2022-06-30109000000 USD20220804Open filing evidence
2022-01-01 – 2022-06-30221000000 USD20220804Open filing evidence
2022-01-01 – 2022-03-31112000000 USD20220505Open filing evidence
2021-01-01 – 2021-12-31461000000 USD20220228Open filing evidence
2021-07-01 – 2021-09-30116000000 USD20211104Open filing evidence
2021-01-01 – 2021-09-30342000000 USD20211104Open filing evidence
2021-04-01 – 2021-06-30114000000 USD20220804Open filing evidence
2021-01-01 – 2021-06-30226000000 USD20220804Open filing evidence
2021-01-01 – 2021-03-31112000000 USD20220505Open filing evidence
2020-01-01 – 2020-12-31402000000 USD20220228Open filing evidence
2020-07-01 – 2020-09-30108000000 USD20211104Open filing evidence
2020-01-01 – 2020-09-30288000000 USD20211104Open filing evidence
2020-04-01 – 2020-06-3085000000 USD20210805Open filing evidence
2020-01-01 – 2020-06-30180000000 USD20210805Open filing evidence
2020-01-01 – 2020-03-3195000000 USD20210506Open filing evidence
2018-12-30 – 2019-12-31368000000 USD20220228Open filing evidence
2019-07-01 – 2019-09-3094000000 USD20201110Open filing evidence
2018-12-30 – 2019-09-30270000000 USD20201110Open filing evidence
2019-04-01 – 2019-06-3090000000 USD20200811Open filing evidence
2018-12-30 – 2019-06-30176000000 USD20200811Open filing evidence
2018-12-30 – 2019-03-3186000000 USD20200514Open filing evidence
2017-12-31 – 2018-12-29387000000 USD20210301Open filing evidence
2017-01-01 – 2017-12-30349000000 USD20200303Open filing evidence

Asia Pacificand Emerging Markets · Material Reconciling Items

Statement Business Segments · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cvet:AsiaPacificandEmergingMarketsMember;srt:ConsolidationItemsAxis=us-gaap:MaterialReconcilingItemsMember
PeriodValueUnitFiledEvidence
2021-01-01 – 2021-12-310 USD20220228Open filing evidence
2021-04-01 – 2021-06-300 USD20210805Open filing evidence
2021-01-01 – 2021-06-300 USD20210805Open filing evidence
2021-01-01 – 2021-03-310 USD20210506Open filing evidence
2020-01-01 – 2020-12-310 USD20220228Open filing evidence
2020-07-01 – 2020-09-300 USD20201110Open filing evidence
2020-01-01 – 2020-09-300 USD20201110Open filing evidence
2020-04-01 – 2020-06-300 USD20210805Open filing evidence
2020-01-01 – 2020-06-300 USD20210805Open filing evidence
2020-01-01 – 2020-03-310 USD20210506Open filing evidence
2018-12-30 – 2019-12-310 USD20220228Open filing evidence
2019-07-01 – 2019-09-300 USD20201110Open filing evidence
2018-12-30 – 2019-09-300 USD20201110Open filing evidence
2019-04-01 – 2019-06-300 USD20200811Open filing evidence
2018-12-30 – 2019-06-300 USD20200811Open filing evidence

Asia Pacificand Emerging Markets · Operating Segments

Statement Business Segments · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cvet:AsiaPacificandEmergingMarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2022-01-01 – 2022-03-31112000000 USD20220505Open filing evidence
2021-01-01 – 2021-12-31461000000 USD20220228Open filing evidence
2021-04-01 – 2021-06-30114000000 USD20210805Open filing evidence
2021-01-01 – 2021-06-30226000000 USD20210805Open filing evidence
2021-01-01 – 2021-03-31112000000 USD20220505Open filing evidence
2020-01-01 – 2020-12-31402000000 USD20220228Open filing evidence
2020-07-01 – 2020-09-30108000000 USD20201110Open filing evidence
2020-01-01 – 2020-09-30288000000 USD20201110Open filing evidence
2020-04-01 – 2020-06-3085000000 USD20210805Open filing evidence
2020-01-01 – 2020-06-30180000000 USD20210805Open filing evidence
2018-12-30 – 2019-12-31368000000 USD20220228Open filing evidence
2019-07-01 – 2019-09-3094000000 USD20201110Open filing evidence
2018-12-30 – 2019-09-30270000000 USD20201110Open filing evidence
2017-12-31 – 2018-12-29387000000 USD20210301Open filing evidence

Asia Pacificand Emerging Markets · Operating Segments · Prescription Management

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cvet:AsiaPacificandEmergingMarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cvet:PrescriptionManagementMember
PeriodValueUnitFiledEvidence
2021-04-01 – 2021-06-300 USD20210805Open filing evidence
2021-01-01 – 2021-06-300 USD20210805Open filing evidence
2020-01-01 – 2020-12-310 USD20210301Open filing evidence
2020-04-01 – 2020-06-300 USD20210805Open filing evidence
2020-01-01 – 2020-06-300 USD20210805Open filing evidence
2018-12-30 – 2019-12-310 USD20210301Open filing evidence
2017-12-31 – 2018-12-290 USD20210301Open filing evidence

Asia Pacificand Emerging Markets · Operating Segments · Software Solutions

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cvet:AsiaPacificandEmergingMarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cvet:SoftwareSolutionsMember
PeriodValueUnitFiledEvidence
2022-01-01 – 2022-03-313000000 USD20220505Open filing evidence
2021-01-01 – 2021-03-313000000 USD20220505Open filing evidence

Asia Pacificand Emerging Markets · Operating Segments · Supply Chain

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cvet:AsiaPacificandEmergingMarketsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cvet:SupplyChainMember
PeriodValueUnitFiledEvidence
2021-04-01 – 2021-06-30112000000 USD20210805Open filing evidence
2021-01-01 – 2021-06-30221000000 USD20210805Open filing evidence
2020-07-01 – 2020-09-30106000000 USD20201110Open filing evidence
2020-01-01 – 2020-09-30282000000 USD20201110Open filing evidence
2020-04-01 – 2020-06-3083000000 USD20210805Open filing evidence
2020-01-01 – 2020-06-30176000000 USD20210805Open filing evidence
2019-07-01 – 2019-09-3092000000 USD20201110Open filing evidence
2018-12-30 – 2019-09-30264000000 USD20201110Open filing evidence

Asia Pacificand Emerging Markets · Prescription Management · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cvet:AsiaPacificandEmergingMarketsMember;srt:ProductOrServiceAxis=cvet:PrescriptionManagementMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2022-01-01 – 2022-03-310 USD20220505Open filing evidence
2021-01-01 – 2021-12-310 USD20220228Open filing evidence
2021-01-01 – 2021-03-310 USD20220505Open filing evidence
2020-01-01 – 2020-12-310 USD20220228Open filing evidence
2018-12-30 – 2019-12-310 USD20220228Open filing evidence

Asia Pacificand Emerging Markets · Software Solutions · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cvet:AsiaPacificandEmergingMarketsMember;srt:ProductOrServiceAxis=cvet:SoftwareSolutionsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2021-04-01 – 2021-06-302000000 USD20210805Open filing evidence
2021-01-01 – 2021-06-305000000 USD20210805Open filing evidence
2020-04-01 – 2020-06-302000000 USD20210805Open filing evidence
2020-01-01 – 2020-06-304000000 USD20210805Open filing evidence

Asia Pacificand Emerging Markets · Supply Chain · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cvet:AsiaPacificandEmergingMarketsMember;srt:ProductOrServiceAxis=cvet:SupplyChainMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2022-01-01 – 2022-03-31109000000 USD20220505Open filing evidence
2021-01-01 – 2021-03-31109000000 USD20220505Open filing evidence

Europe Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cvet:EuropeSegmentMember
PeriodValueUnitFiledEvidence
2022-04-01 – 2022-06-30325000000 USD20220804Open filing evidence
2022-01-01 – 2022-06-30665000000 USD20220804Open filing evidence
2022-01-01 – 2022-03-31340000000 USD20220505Open filing evidence
2021-01-01 – 2021-12-311412000000 USD20220228Open filing evidence
2021-07-01 – 2021-09-30353000000 USD20211104Open filing evidence
2021-01-01 – 2021-09-301080000000 USD20211104Open filing evidence
2021-04-01 – 2021-06-30362000000 RestatedUSD20220804Open filing evidence
2021-01-01 – 2021-06-30717000000 RestatedUSD20220804Open filing evidence
2021-01-01 – 2021-03-31355000000 RestatedUSD20220505Open filing evidence
2020-01-01 – 2020-12-311571000000 USD20220228Open filing evidence
2020-07-01 – 2020-09-30403000000 USD20211104Open filing evidence
2020-01-01 – 2020-09-301166000000 USD20211104Open filing evidence
2020-04-01 – 2020-06-30342000000 USD20210805Open filing evidence
2020-01-01 – 2020-06-30764000000 USD20210805Open filing evidence
2020-01-01 – 2020-03-31422000000 USD20210506Open filing evidence
2018-12-30 – 2019-12-311509000000 USD20220228Open filing evidence
2019-07-01 – 2019-09-30384000000 USD20201110Open filing evidence
2018-12-30 – 2019-09-301114000000 USD20201110Open filing evidence
2019-04-01 – 2019-06-30370000000 USD20200811Open filing evidence
2018-12-30 – 2019-06-30731000000 USD20200811Open filing evidence
2018-12-30 – 2019-03-31361000000 USD20200514Open filing evidence
2017-12-31 – 2018-12-291463000000 USD20210301Open filing evidence
2017-01-01 – 2017-12-301373000000 USD20200303Open filing evidence

Europe Segment · Material Reconciling Items

Statement Business Segments · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cvet:EuropeSegmentMember;srt:ConsolidationItemsAxis=us-gaap:MaterialReconcilingItemsMember
PeriodValueUnitFiledEvidence
2021-01-01 – 2021-12-31-18000000 USD20220228Open filing evidence
2021-04-01 – 2021-06-30-4000000 USD20210805Open filing evidence
2021-01-01 – 2021-06-30-10000000 USD20210805Open filing evidence
2020-01-01 – 2020-12-31-13000000 USD20220228Open filing evidence
2020-07-01 – 2020-09-30-3000000 USD20201110Open filing evidence
2020-01-01 – 2020-09-30-9000000 USD20201110Open filing evidence
2020-04-01 – 2020-06-30-2000000 USD20210805Open filing evidence
2020-01-01 – 2020-06-30-6000000 USD20210805Open filing evidence
2018-12-30 – 2019-12-31-14000000 USD20220228Open filing evidence
2019-07-01 – 2019-09-30-3000000 USD20201110Open filing evidence
2018-12-30 – 2019-09-30-10000000 USD20201110Open filing evidence
2019-04-01 – 2019-06-30-3000000 USD20200811Open filing evidence
2018-12-30 – 2019-06-30-7000000 USD20200811Open filing evidence
2017-12-31 – 2018-12-29-10000000 USD20210301Open filing evidence

Europe Segment · Operating Segments

Statement Business Segments · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cvet:EuropeSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2022-01-01 – 2022-03-31344000000 USD20220505Open filing evidence
2021-01-01 – 2021-12-311412000000 USD20220228Open filing evidence
2021-07-01 – 2021-09-30353000000 USD20211104Open filing evidence
2021-01-01 – 2021-09-301080000000 USD20211104Open filing evidence
2021-01-01 – 2021-03-31361000000 USD20220505Open filing evidence
2020-01-01 – 2020-12-311571000000 USD20220228Open filing evidence
2020-07-01 – 2020-09-30403000000 USD20211104Open filing evidence
2020-01-01 – 2020-09-301166000000 USD20211104Open filing evidence
2018-12-30 – 2019-12-311509000000 USD20220228Open filing evidence
2017-12-31 – 2018-12-291463000000 USD20210301Open filing evidence

Europe Segment · Operating Segments · Prescription Management

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cvet:EuropeSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cvet:PrescriptionManagementMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-12-310 USD20210301Open filing evidence
2018-12-30 – 2019-12-310 USD20210301Open filing evidence
2017-12-31 – 2018-12-290 USD20210301Open filing evidence

Europe Segment · Operating Segments · Software Solutions

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cvet:EuropeSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cvet:SoftwareSolutionsMember
PeriodValueUnitFiledEvidence
2022-01-01 – 2022-03-313000000 USD20220505Open filing evidence
2021-01-01 – 2021-03-313000000 USD20220505Open filing evidence

Europe Segment · Prescription Management · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cvet:EuropeSegmentMember;srt:ProductOrServiceAxis=cvet:PrescriptionManagementMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2022-01-01 – 2022-03-310 USD20220505Open filing evidence
2021-01-01 – 2021-12-310 USD20220228Open filing evidence
2021-01-01 – 2021-03-310 USD20220505Open filing evidence
2020-01-01 – 2020-12-310 USD20220228Open filing evidence
2018-12-30 – 2019-12-310 USD20220228Open filing evidence

Europe Segment · Software Solutions · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cvet:EuropeSegmentMember;srt:ProductOrServiceAxis=cvet:SoftwareSolutionsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-12-3110000000 USD20210301Open filing evidence
2018-12-30 – 2019-12-3110000000 USD20210301Open filing evidence
2017-12-31 – 2018-12-2911000000 USD20210301Open filing evidence

Europe Segment · Supply Chain · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cvet:EuropeSegmentMember;srt:ProductOrServiceAxis=cvet:SupplyChainMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2022-01-01 – 2022-03-31337000000 USD20220505Open filing evidence
2021-01-01 – 2021-03-31352000000 USD20220505Open filing evidence
2020-01-01 – 2020-12-311574000000 USD20210301Open filing evidence
2018-12-30 – 2019-12-311513000000 USD20210301Open filing evidence
2017-12-31 – 2018-12-291462000000 USD20210301Open filing evidence

North America Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cvet:NorthAmericaSegmentMember
PeriodValueUnitFiledEvidence
2022-04-01 – 2022-06-30783000000 USD20220804Open filing evidence
2022-01-01 – 2022-06-301479000000 USD20220804Open filing evidence
2022-01-01 – 2022-03-31696000000 USD20220505Open filing evidence
2021-01-01 – 2021-12-312719000000 USD20220228Open filing evidence
2021-07-01 – 2021-09-30697000000 USD20211104Open filing evidence
2021-01-01 – 2021-09-302045000000 USD20211104Open filing evidence
2021-04-01 – 2021-06-30713000000 USD20220804Open filing evidence
2021-01-01 – 2021-06-301348000000 USD20220804Open filing evidence
2021-01-01 – 2021-03-31635000000 USD20220505Open filing evidence
2020-01-01 – 2020-12-312377000000 USD20220228Open filing evidence
2020-07-01 – 2020-09-30618000000 USD20211104Open filing evidence
2020-01-01 – 2020-09-301771000000 USD20211104Open filing evidence
2020-04-01 – 2020-06-30602000000 USD20210805Open filing evidence
2020-01-01 – 2020-06-301152000000 USD20210805Open filing evidence
2020-01-01 – 2020-03-31550000000 USD20210506Open filing evidence
2018-12-30 – 2019-12-312111000000 USD20220228Open filing evidence
2019-07-01 – 2019-09-30543000000 USD20201110Open filing evidence
2018-12-30 – 2019-09-301592000000 USD20201110Open filing evidence
2019-04-01 – 2019-06-30552000000 USD20200811Open filing evidence
2018-12-30 – 2019-06-301049000000 USD20200811Open filing evidence
2018-12-30 – 2019-03-31497000000 USD20200514Open filing evidence
2017-12-31 – 2018-12-291939000000 USD20210301Open filing evidence
2017-01-01 – 2017-12-301876000000 USD20200303Open filing evidence

North America Segment · Material Reconciling Items

Statement Business Segments · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cvet:NorthAmericaSegmentMember;srt:ConsolidationItemsAxis=us-gaap:MaterialReconcilingItemsMember
PeriodValueUnitFiledEvidence
2021-07-01 – 2021-09-30-22000000 USD20211104Open filing evidence
2021-01-01 – 2021-09-30-69000000 USD20211104Open filing evidence
2021-04-01 – 2021-06-30-25000000 USD20210805Open filing evidence
2021-01-01 – 2021-06-30-47000000 USD20210805Open filing evidence
2020-01-01 – 2020-12-31-76000000 USD20210301Open filing evidence
2020-07-01 – 2020-09-30-18000000 USD20211104Open filing evidence
2020-01-01 – 2020-09-30-56000000 USD20211104Open filing evidence
2020-04-01 – 2020-06-30-22000000 USD20210805Open filing evidence
2020-01-01 – 2020-06-30-39000000 USD20210805Open filing evidence
2018-12-30 – 2019-12-31-33000000 USD20210301Open filing evidence
2019-07-01 – 2019-09-30-13000000 USD20201110Open filing evidence
2018-12-30 – 2019-09-30-21000000 USD20201110Open filing evidence
2019-04-01 – 2019-06-30-7000000 USD20200811Open filing evidence
2018-12-30 – 2019-06-30-8000000 USD20200811Open filing evidence
2017-12-31 – 2018-12-29-2000000 USD20210301Open filing evidence

North America Segment · Operating Segments

Statement Business Segments · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cvet:NorthAmericaSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2022-04-01 – 2022-06-30783000000 USD20220804Open filing evidence
2022-01-01 – 2022-06-301479000000 USD20220804Open filing evidence
2022-01-01 – 2022-03-31696000000 USD20220505Open filing evidence
2021-01-01 – 2021-12-312719000000 USD20220228Open filing evidence
2021-07-01 – 2021-09-30697000000 USD20211104Open filing evidence
2021-01-01 – 2021-09-302045000000 USD20211104Open filing evidence
2021-04-01 – 2021-06-30713000000 USD20220804Open filing evidence
2021-01-01 – 2021-06-301348000000 USD20220804Open filing evidence
2021-01-01 – 2021-03-31635000000 USD20220505Open filing evidence
2020-01-01 – 2020-12-312377000000 USD20220228Open filing evidence
2020-07-01 – 2020-09-30618000000 USD20211104Open filing evidence
2020-01-01 – 2020-09-301771000000 USD20211104Open filing evidence
2020-04-01 – 2020-06-30602000000 USD20210805Open filing evidence
2020-01-01 – 2020-06-301152000000 USD20210805Open filing evidence
2018-12-30 – 2019-12-312111000000 USD20220228Open filing evidence
2017-12-31 – 2018-12-291939000000 USD20210301Open filing evidence

North America Segment · Operating Segments · Prescription Management

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cvet:NorthAmericaSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cvet:PrescriptionManagementMember
PeriodValueUnitFiledEvidence
2022-04-01 – 2022-06-30163000000 USD20220804Open filing evidence
2022-01-01 – 2022-06-30303000000 USD20220804Open filing evidence
2021-04-01 – 2021-06-30131000000 USD20220804Open filing evidence
2021-01-01 – 2021-06-30243000000 USD20220804Open filing evidence
2020-01-01 – 2020-12-31406000000 USD20210301Open filing evidence
2020-04-01 – 2020-06-30110000000 USD20210805Open filing evidence
2020-01-01 – 2020-06-30195000000 USD20210805Open filing evidence
2018-12-30 – 2019-12-31246000000 USD20210301Open filing evidence
2017-12-31 – 2018-12-290 USD20210301Open filing evidence

North America Segment · Operating Segments · Software Solutions

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cvet:NorthAmericaSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cvet:SoftwareSolutionsMember
PeriodValueUnitFiledEvidence
2022-01-01 – 2022-03-3119000000 USD20220505Open filing evidence
2021-01-01 – 2021-03-3120000000 USD20220505Open filing evidence

North America Segment · Operating Segments · Supply Chain

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cvet:NorthAmericaSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=cvet:SupplyChainMember
PeriodValueUnitFiledEvidence
2022-04-01 – 2022-06-30599000000 USD20220804Open filing evidence
2022-01-01 – 2022-06-301136000000 USD20220804Open filing evidence
2021-04-01 – 2021-06-30562000000 RestatedUSD20220804Open filing evidence
2021-01-01 – 2021-06-301065000000 RestatedUSD20220804Open filing evidence
2020-04-01 – 2020-06-30495000000 USD20210805Open filing evidence
2020-01-01 – 2020-06-30956000000 USD20210805Open filing evidence

North America Segment · Prescription Management · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cvet:NorthAmericaSegmentMember;srt:ProductOrServiceAxis=cvet:PrescriptionManagementMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2022-01-01 – 2022-03-31140000000 USD20220505Open filing evidence
2021-01-01 – 2021-12-31503000000 USD20220228Open filing evidence
2021-07-01 – 2021-09-30129000000 USD20211104Open filing evidence
2021-01-01 – 2021-09-30372000000 USD20211104Open filing evidence
2021-01-01 – 2021-03-31112000000 USD20220505Open filing evidence
2020-01-01 – 2020-12-31406000000 USD20220228Open filing evidence
2020-07-01 – 2020-09-30104000000 USD20211104Open filing evidence
2020-01-01 – 2020-09-30298000000 USD20211104Open filing evidence
2018-12-30 – 2019-12-31246000000 USD20220228Open filing evidence

North America Segment · Software Solutions · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cvet:NorthAmericaSegmentMember;srt:ProductOrServiceAxis=cvet:SoftwareSolutionsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2021-07-01 – 2021-09-3020000000 USD20211104Open filing evidence
2021-01-01 – 2021-09-3060000000 USD20211104Open filing evidence
2020-07-01 – 2020-09-3020000000 USD20211104Open filing evidence
2020-01-01 – 2020-09-3060000000 USD20211104Open filing evidence

North America Segment · Supply Chain · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cvet:NorthAmericaSegmentMember;srt:ProductOrServiceAxis=cvet:SupplyChainMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2022-01-01 – 2022-03-31537000000 USD20220505Open filing evidence
2021-07-01 – 2021-09-30570000000 USD20211104Open filing evidence
2021-01-01 – 2021-09-301682000000 USD20211104Open filing evidence
2021-01-01 – 2021-03-31503000000 USD20220505Open filing evidence
2020-07-01 – 2020-09-30512000000 USD20211104Open filing evidence
2020-01-01 – 2020-09-301469000000 USD20211104Open filing evidence